Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

BACKGROUND: The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer (NSCLC) patients. However, the association between therapeutic efficacy and the development of immune-related adverse events (irAEs) remains unclear in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Kana, Mitsuishi, Yoichiro, Shimada, Naoko, Kawakami, Yuta, Miura, Keita, Miyawaki, Taichi, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shibayama, Rina, Nojiri, Shuko, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535983/
https://www.ncbi.nlm.nih.gov/pubmed/36203123
http://dx.doi.org/10.1186/s12885-022-10133-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535983/
https://www.ncbi.nlm.nih.gov/pubmed/36203123
http://dx.doi.org/10.1186/s12885-022-10133-1

Ejemplares similares